Ivan Kairatov is a seasoned voice in biopharmaceutical innovation, specializing in the complex intersections of metabolic signaling and oncology. With years spent navigating the intricacies of research and development, he has witnessed how the industry struggles to tackle the secondary symptoms of
The transition of a revolutionary medical concept from the isolation of a laboratory bench to the bedside of a critically ill patient represents one of the most significant challenges in modern oncology. The Ludwig Institute for Cancer Research recently entered a transformative phase by appointing
While CAR-T cell therapy has revolutionized the treatment of liquid cancers, the dense and deceptive landscape of solid tumors like glioblastoma has long remained an impenetrable fortress—until now. Glioblastoma is recognized as one of the most aggressive malignancies in existence, with a five-year
The traditional view of acute myeloid leukemia as a localized disease of the bone marrow is undergoing a radical transformation as researchers uncover the sophisticated ways this cancer colonizes distant organs like the lungs. While clinical experts have long recognized that respiratory failure is
Ivan Kairatov is a seasoned biopharma expert with a distinguished career in research and development, particularly focusing on how cutting-edge technology reshapes clinical outcomes for rare diseases. Today, we sit down to discuss the recent FDA Priority Review of Enspryng, a potential breakthrough
The profound silence experienced by individuals living with advanced neurodegenerative diseases often hides a vibrant internal world that lacks a reliable physical outlet for expression. Traditional methods of bridging this gap have typically existed at two extremes: non-invasive sensors that
